EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Vir Biotechnology (NASDAQ:VIR) Trading Down 10.4% - What's Next?
Vir Biotechnology Receives Buy Rating: Promising TCE Programs and Strategic Focus Boost Growth Outlook
Vir Biotechnology (NASDAQ:VIR) Shares Down 10.4% - Here's Why
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Vir Biotechnology (NASDAQ:VIR) Stock Price Down 10.4% - Here's What Happened
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Edgewise Therapeutics (EWTX) and Avadel Pharmaceuticals (AVDL) | Markets Insider
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Vir Biotechnology (VIR) | Markets Insider
Vir Biotechnology (NASDAQ:VIR) Hits New 1-Year High on Analyst Upgrade
Vir Biotechnology (NASDAQ:VIR) Earns "Buy" Rating from HC Wainwright
Vir Biotechnology Announces Positive Phase 1 Clinical Data for Dual Masked T-Cell Engagers
Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week High - Time to Buy?
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 By Investing.com
Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 10,960 Shares of Stock
Morgan Stanley lifts Vir Biotech stock rating, doubles price target By Investing.com
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates - January 9, 2025 - Zacks.com
Vir Biotechnology's Early Promise in Clinical Trials Warrants Hold Rating Amid Uncertainties
Vir Biotechnology's Early Stage Developments and Valuation Lead to Hold Rating Amid Long-Term Promise and Near-Term Uncertainties
Vir Biotechnology price target raised to $14 from $10 at JPMorgan
Goldman Sachs maintains Buy on Vir Biotechnology stock, $28 target By Investing.com
Vir Biotechnology (NASDAQ:VIR) Trading Up 7.1% - What's Next?
JPMorgan raises Vir Biotechnology stock target to $14 By Investing.com
Vir Biotechnology's Promising TCE Oncology Assets Earn Buy Rating from Joseph Stringer
Vir Biotechnology director Vicki L. Sato sells $137,219 in stock By Investing.com
Vir Biotechnology (NASDAQ:VIR) Shares Gap Up - What's Next?
Vir Biotechnology stock hits 52-week high of $13.18 By Investing.com
Vir Biotechnology Reports Encouraging Phase 1 Data For Two Cancer Drug Candidates; Stock UP
Vir Biotechnology stock soars on promising trial data By Investing.com
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC | Morningstar
Early data validate Vir's newly acquired dual-masked TCE therapies | BioWorld
Vir Biotechnology (NASDAQ:VIR) Trading 7.1% Higher - What's Next?
